COO’s $1.72 Buy Signals Confidence in Acrivon’s Upcoming Clinical MilestoneCOO’s $1.72 buy signals confidence in Acrivon’s precision‑proteomics; could spark a short‑term rally if Q3 trial data arrive.Acrivon Therapeutics Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated DirectorDealingsBot 15/01/2026, 22:56 3 minutes to read
